Literature DB >> 26768237

Epigenetic Therapeutics: A New Weapon in the War Against Cancer.

Nita Ahuja1, Anup R Sharma1, Stephen B Baylin1.   

Abstract

The past 15 years have seen an explosion of discoveries related to the cellular regulation of phenotypes through epigenetic mechanisms. This regulation provides a software that packages DNA, without changing the primary base sequence, to establish heritable patterns of gene expression. In cancer, many aspects of the epigenome, controlled by DNA methylation, chromatin, and nucleosome positioning, are altered as one means by which tumor cells maintain abnormal states of self-renewal at the expense of normal maturation. Epigenetic and genetic abnormalities thus collaborate in cancer initiation and progression, as exemplified by frequent mutations in genes encoding proteins that control the epigenome. There is growing emphasis on using epigenetic therapies to reprogram neoplastic cells toward a normal state. Many agents targeting epigenetic regulation are under development and entering clinical trials. This review highlights the promise that epigenetic therapy, often in combination with other therapies, will become a potent tool for cancer management over the next decade.

Entities:  

Keywords:  DNA methyltransferase inhibitor; epigenetics; histone deacetylase inhibitor therapy

Mesh:

Substances:

Year:  2016        PMID: 26768237      PMCID: PMC4937439          DOI: 10.1146/annurev-med-111314-035900

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  90 in total

1.  A complex Polycomb issue: the two faces of EZH2 in cancer.

Authors:  Hanno Hock
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

2.  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.

Authors:  Katherine B Chiappinelli; Pamela L Strissel; Alexis Desrichard; Huili Li; Christine Henke; Benjamin Akman; Alexander Hein; Neal S Rote; Leslie M Cope; Alexandra Snyder; Vladimir Makarov; Sadna Budhu; Sadna Buhu; Dennis J Slamon; Jedd D Wolchok; Drew M Pardoll; Matthias W Beckmann; Cynthia A Zahnow; Taha Merghoub; Taha Mergoub; Timothy A Chan; Stephen B Baylin; Reiner Strick
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 3.  A new world of Polycombs: unexpected partnerships and emerging functions.

Authors:  Yuri B Schwartz; Vincenzo Pirrotta
Journal:  Nat Rev Genet       Date:  2013-11-12       Impact factor: 53.242

Review 4.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

5.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

Review 7.  Cancer genome-sequencing study design.

Authors:  Jill C Mwenifumbo; Marco A Marra
Journal:  Nat Rev Genet       Date:  2013-05       Impact factor: 53.242

8.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

Review 9.  HDAC inhibitors: roles of DNA damage and repair.

Authors:  Carine Robert; Feyruz V Rassool
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 10.  Epigenetic modifications as therapeutic targets.

Authors:  Theresa K Kelly; Daniel D De Carvalho; Peter A Jones
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

View more
  102 in total

Review 1.  Epigenetic control in skin development, homeostasis and injury repair.

Authors:  Sangjo Kang; Gopal Chovatiya; Tudorita Tumbar
Journal:  Exp Dermatol       Date:  2019-02-12       Impact factor: 3.960

Review 2.  Mutant ATRX: uncovering a new therapeutic target for glioma.

Authors:  Santiago Haase; María Belén Garcia-Fabiani; Stephen Carney; David Altshuler; Felipe J Núñez; Flor M Méndez; Fernando Núñez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

3.  Epigenetic modifier drugs trigger widespread transcription of endogenous retroviruses.

Authors:  Dixie L Mager; Matthew C Lorincz
Journal:  Nat Genet       Date:  2017-06-28       Impact factor: 38.330

Review 4.  Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer.

Authors:  Carl Koschmann; Felipe J Nunez; Flor Mendez; Jacqueline A Brosnan-Cashman; Alan K Meeker; Pedro R Lowenstein; Maria G Castro
Journal:  Cancer Res       Date:  2017-01-06       Impact factor: 12.701

Review 5.  DNA methylation profiles in cancer diagnosis and therapeutics.

Authors:  Yunbao Pan; Guohong Liu; Fuling Zhou; Bojin Su; Yirong Li
Journal:  Clin Exp Med       Date:  2017-07-27       Impact factor: 3.984

Review 6.  Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B.

Authors:  Xupeng Hong; Elena S Kim; Haitao Guo
Journal:  Hepatology       Date:  2017-11-06       Impact factor: 17.425

Review 7.  Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics.

Authors:  Himadri Patel; Pritish Nilendu; Devashree Jahagirdar; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cancer Biol Ther       Date:  2017-12-08       Impact factor: 4.742

8.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

Review 9.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

Review 10.  Biomarkers of genome instability and cancer epigenetics.

Authors:  Adriana H O Reis; Fernando R Vargas; Bernardo Lemos
Journal:  Tumour Biol       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.